The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of ...
1.0 Credit / Neurology
View More
Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis
1.0 Credit / Immunology, Neurology
View More
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
1 Credit / Cardiology, Neurology
View More
The Impact of Pharmacists and Pharmacy Technicians in Recognizing and Responding to Human Trafficking (Pharmac...
2.0 Credits / Human Trafficking, Law
View More
From Treatment to Prevention: Navigating the Expanding Hereditary Angioedema Treatment Landscape
August 13, 2025 | 1:00 PM & 8:00 PM EDT
View More
Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape for Managed Care Professi...
August 19, 2025 | 1:00 PM & 8:00 PM ET
View More
Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models
August 21, 2025 | 1:00 PM ET & 8:00 PM ET
View More
Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape
1.0 Credit / Gastroenterology, Immunology, Rare Diseases
View More
Biosimilars Drive Savings and Access, Yet Looming Development Gap Threatens Future
September 23rd 2025Biosimilars and generics drive significant health care savings, yet a concerning lack of biosimilar development for biologics set to lose exclusivity in the next 10 years threatens future access and affordability.
Denosumab Biosimilar LY01011 Shows Equivalence to Reference Product for Bone Metastases
August 14th 2025Biosimilar LY01011 is equivalent to the reference product denosumab for treating bone metastases in solid tumors, demonstrating similar efficacy in reducing bone metabolism biomarkers, comparable safety profiles, and a lack of unexpected adverse reactions.